CervoMed Inc. (CRVO) Stock

CervoMed Inc. (CRVO) is a Healthcare stock trading at $3.92 (as of 2026-06-18), with a market capitalization of $48.39M and a trailing P/E of -1.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

CervoMed Inc. is a clinical-stage biotechnology company developing and commercializing drug treatments for neurodegenerative conditions. Its program centers on neflamapimod, an orally administered small-molecule intended for brain-penetrant therapy in dementia with Lewy bodies, Alzheimer’s disease, and brain stroke recovery.

Valuation — source: SEC EDGAR (first-party)
Price	$3.92
Market Cap	$48.39M
P/E Ratio	-1.3
Price / Book	3.70
Price / Sales	18.79
DCF Value (model)	$-42.23
DCF Upside vs Price	-1177.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$4.01M
Net Margin	-673.1%
Return on Equity	-282.9%
Current Ratio	3.25
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	53.6%

Financial Health — source: SEC EDGAR
Altman Z-Score	-4.25 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.3
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-106.3%
vs Industry	-107.7%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	AWM Investment Company, Inc. ($6.28M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	John J. Alam
Employees	15
Country	US
IPO Date	2008-05-23

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.